Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Multicenter Phase III Clinical Trial of HB0025 Injection Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-Line Treatment for Advanced or Recurrent Endometrial Cancer

NCT07902999 is registered in ClinicalTrials.gov with Shanghai Huaota Biopharmaceutical Co., Ltd. as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07902999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Multicenter Phase III Clinical Trial of HB0025 Injection Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-Line Treatment for Advanced or Recurrent Endometrial Cancer
Lead sponsor
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
October 20, 2026
Completion date
June 26, 2031
Enrollment
333 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

first-line pmmr endometrial cancer

Arms

As registered; 2 arms.

  • HB0025 ExperimentalCarboplatin injection, HB0025 Injection, Paclitaxel injection

    HB0025 combined with Paclitaxel for Injection plus Carboplatin for Injection

  • Placebo Placebo comparatorCarboplatin injection, Paclitaxel injection, Placebo matching HB0025

    Placebo combined with Paclitaxel for Injection plus Carboplatin for Injection

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Progression-free survival (PFS) Up to 34 months

    PFS is defined as the time from the date of randomization till the first documentation of disease progression (per RECIST v1.1 criteria) assessed by the Blinded Independent Central Review or death due to any cause (whichever occurs first)

Lead sponsor's other trials

Shanghai Huaota Biopharmaceutical Co., Ltd., most recent start first.